A5060633589- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Glioma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Medical Imaging and Pathology Studies
- Catalytic Alkyne Reactions
- Synthesis and Biological Activity
- Neuroblastoma Research and Treatments
- Chemical Synthesis and Analysis
- Colorectal Cancer Treatments and Studies
- Cyclization and Aryne Chemistry
- Marine Sponges and Natural Products
- Synthetic Organic Chemistry Methods
- Cancer Research and Treatments
University College London
2017
Cancer Research UK Manchester Institute
2013
University of Manchester
2013
Manchester Academic Health Science Centre
2013
Abstract The phosphoinositide 3-kinase (PI3K) pathway is deregulated in a range of cancers, and several targeted inhibitors are entering the clinic. This study aimed to investigate whether positron emission tomography tracer 3′-deoxy-3′-[18F]fluorothymidine ([18F]-FLT) suitable mark effect novel PI3K inhibitor GDC-0941, which has entered phase II clinical trial. CBA nude mice bearing U87 glioma HCT116 colorectal xenografts were imaged at baseline with [18F]-FLT acute (18 hours) chronic (186...
Alkynyl sulfonamides undergo sequential 1,4- then 1,2-addition/rearrangement with lithium acetylides to yield enediynes in the absence of any promoters or catalysts. Mechanistic investigations suggest that reaction proceeds <italic>via</italic> a novel electrophilic carbenoid distinct reactivity compared those previously described.
<p>PDF file - 46 KB, Chronic dosing with GDC-0941 leads to an increase in MAP-kinase pathway signaling sensitive tumors.</p>
<p>PDF file - 75 KB, Uptake of 18F-FDG decreases significantly after ~18h GDC-0941 treatment in U87, but not HCT116, tumors.</p>
<p>PDF file - 74 KB, GDC-0941 inhibits hypoxic signaling in drug sensitive U87 tumors.</p>
<p>PDF file - 65 KB, Acute dosing with GDC-0941 leads to an increase in apoptotic signaling sensitive tumors.</p>
<p>PDF file - 51 KB</p>
<p>PDF file - 74 KB, GDC-0941 inhibits hypoxic signaling in drug sensitive U87 tumors.</p>
<p>PDF file - 65 KB, Acute dosing with GDC-0941 leads to an increase in apoptotic signaling sensitive tumors.</p>
<p>PDF file - 51 KB</p>
<p>PDF file - 75 KB, Uptake of 18F-FDG decreases significantly after ~18h GDC-0941 treatment in U87, but not HCT116, tumors.</p>
<p>PDF file - 46 KB, Chronic dosing with GDC-0941 leads to an increase in MAP-kinase pathway signaling sensitive tumors.</p>
<div>Abstract<p>The phosphoinositide 3-kinase (PI3K) pathway is deregulated in a range of cancers, and several targeted inhibitors are entering the clinic. This study aimed to investigate whether positron emission tomography tracer 3′-deoxy-3′-[<sup>18</sup>F]fluorothymidine ([<sup>18</sup>F]-FLT) suitable mark effect novel PI3K inhibitor GDC-0941, which has entered phase II clinical trial. CBA nude mice bearing U87 glioma HCT116 colorectal xenografts were...
<div>Abstract<p>The phosphoinositide 3-kinase (PI3K) pathway is deregulated in a range of cancers, and several targeted inhibitors are entering the clinic. This study aimed to investigate whether positron emission tomography tracer 3′-deoxy-3′-[<sup>18</sup>F]fluorothymidine ([<sup>18</sup>F]-FLT) suitable mark effect novel PI3K inhibitor GDC-0941, which has entered phase II clinical trial. CBA nude mice bearing U87 glioma HCT116 colorectal xenografts were...